Correction to “Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsOral health in cancer treatment · Rheumatoid Arthritis Research and Therapies · Acute Lymphoblastic Leukemia research
Hu, Z., Escalera‐Joy, A., Ashcraft, E., Acharya, R., Jeha, S., Cheng, C. and Pui, C.‐H. (2024), Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing. Cancer Med, 13: e70351. https://doi.org/10.1002/cam4.70351.
In paragraph 1, section 2.2 | MTX Concentration Monitoring, the text “using the ARK diagnostics homogeneous enzyme immunoassay (ARK Diagnostics', Fremont, CA)” was incorrect. It should be changed to “using assay by a fluorescence polarization immunoassay technique with a TDx/FLx analyzer (Abbott Diagnostics, Chicago, Illinois, U.S.A.).” The referenced citation 20 should read “P. R. Oeltgen, W. A. Shank Jr, R. A. Blouin, T. Clark.,” “Clinical Evaluation of the Abbott TDx Fluorescence Polarization Immunoassay Analyzer,” “Therapeutic Drug Monitoring 6 no. 3 (1984): 360–367.”
We apologize for these errors.